Risk of incident chronic kidney disease is better reduced by bedtime than upon-awakening ingestion of hypertension medications

Hypertension Research : Official Journal of the Japanese Society of Hypertension
Ramón C HermidaJosé R Fernández


This trial investigated whether therapy with the entire daily dose of ≥1 hypertension medications at bedtime exerts a greater reduction in the risk of incident chronic kidney disease (CKD) than therapy with all medications upon awakening. We conducted a prospective, open-label, blinded endpoint trial of 2078 hypertensive patients without CKD (1017 men/1061 women, 53.6 ± 13.7 years of age) randomized to ingest all their prescribed hypertension medications upon awakening (n = 1041) or the entire daily dose of ≥1 of those medications at bedtime (n = 1037). During a 5.9-year median follow-up, 368 participants developed CKD. Patients of the bedtime, compared with the morning, treatment group showed (i) significantly lower asleep blood pressure (BP) mean, greater sleep-time relative BP decline, and attenuated prevalence of non-dipping at the final evaluation (38 vs. 55%; P < 0.001); and (ii) a significantly lower hazard ratio of CKD, adjusted for the significant influential characteristics of age, serum creatinine, urinary albumin, type 2 diabetes, previous cardiovascular event, asleep systolic BP mean, and sleep-time relative systolic BP decline (0.27 (95% confidence interval: 0.21-0.36); event-rate 8.3 vs. 27.1% in the bedtime and ...Continue Reading


Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Oct 29, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Johannes F E MannUNKNOWN HOPE Investigators
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Sep 22, 2010·Chronobiology International·Ramón C HermidaJosé R Fernández
Jun 7, 2011·Sleep Medicine Reviews·Francesco PortaluppiFabio Fabbian
Jun 29, 2011·Archives of Internal Medicine·Roberto MinutoloLuca De Nicola
Sep 3, 2011·Journal of the American College of Cardiology·Ramón C HermidaJosé R Fernández
Sep 22, 2011·Journal of Korean Medical Science·Hye Rim AnKyu Bok Choi
Oct 7, 2011·The Cochrane Database of Systematic Reviews·Ping ZhaoZhengrong Wang
Oct 26, 2011·Journal of the American Society of Nephrology : JASN·Ramón C HermidaJosé R Fernández
Oct 20, 2012·Chronobiology International·Ramón C HermidaFrancesco Portaluppi
Jan 1, 2013·Kidney International Supplements
Dec 30, 2014·Diabetes Care·UNKNOWN American Diabetes Association
Dec 15, 2015·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Ramón C HermidaFrancesco Portaluppi
May 28, 2016·American Journal of Nephrology·Jordana B CohenPeter P Reese
Dec 3, 2016·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Naro OhashiHideo Yasuda
Apr 30, 2017·Journal of the American Society of Nephrology : JASN·Ramón C HermidaJosé R Fernández

❮ Previous
Next ❯


Jun 17, 2020·Expert Opinion on Pharmacotherapy·Ramón C HermidaJosé R Fernández
Aug 11, 2020·Current Cardiology Reports·Ramón C HermidaJosé R Fernández
Mar 4, 2020·Toxins·Sol CarriazoAlberto Ortiz

❮ Previous
Next ❯

Clinical Trials Mentioned


Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.